Business, energy, technology, markets and global industry news from Business News Today

CDK4/6 resistance

Pharma & Biotech

Is Avenzo’s AVZO-021 the next big player in HR+/HER2- metastatic breast cancer?

Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.

Read More